Quantum BioPharma Advances Phase 2 Trial for Mast Cell Activation Syndrome Treatment
TL;DR
Quantum BioPharma (NASDAQ: QNTM) received HREC approval in Australia for a Phase 2 trial targeting chronic pain.
FSD202, based on ultra-micronized PEA, aims to reduce pain in patients with MCAS by targeting inflammation-related conditions.
The trial may offer a new therapeutic option for MCAS, a debilitating disorder, emphasizing the need for safe alternatives.
Quantum BioPharma's FSD202 trial aims to advance clinical development in treating chronic pain with innovative biotech solutions.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma has obtained human ethics review committee approval in Australia to initiate a Phase 2 clinical trial evaluating FSD202 for treating chronic widespread musculoskeletal nociplastic pain linked to idiopathic Mast Cell Activation Syndrome (MCAS).
The randomized, double-blind, placebo-controlled study will enroll 60 patients and assess pain reduction over a 56-day period. FSD202, which is based on ultra-micronized palmitoylethanolamide (PEA), represents a potential breakthrough for patients suffering from this debilitating disorder that currently lacks a definitive cure.
The trial's significance lies in its potential to provide a novel therapeutic approach for MCAS patients. By targeting inflammation-related conditions, FSD202 could offer an alternative treatment strategy for individuals experiencing chronic pain associated with this complex syndrome.
Quantum BioPharma's approach underscores the growing focus on developing targeted treatments for conditions with limited existing medical interventions. The company's commitment to advancing clinical development demonstrates the ongoing efforts to address unmet medical needs in challenging therapeutic areas.
Curated from InvestorBrandNetwork (IBN)
